Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of E5501 versus eltrombopag in adults with chronic immune thrombocytopenia
NL-OMON37816Phase 3Withdrawn
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avatrombopag and eltrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Durable platelet response rate and Long-term safety and tolerability of E5501. Planned start May 2012; status: withdrawn.
02
Drugs
avatrombopageltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON37816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37816.